Anti-CD46 antibodies and methods of use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11434301
APP PUB NO 20190276553A1
SERIAL NO

16348135

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Aftab, Blake T Thousand Oaks, US 12 55
Behrens, Christopher R San Francisco, US 6 35
Liu, Bin San Francisco, US 1027 7414
Sherbenou, Daniel W Denver, US 2 5
Su, Yang South San Francisco, US 62 240

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Mar 6, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 6, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 6, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00